TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

Inclusion Criteria:

* 1\) Age 18-70 years old, gender is not limited.
* 2)The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL).
* 3)Patients must have at least one tumor lesion that can be accurately measured.
* 4)Conform to any of the following criteria (1) multiple nodules \>3; (2) ≥2 nodules, any of which is \>3 cm; (3) invasion of the portal vein or hepatic vein.
* 5)According to the 2022 edition of the Chinese guidelines for the diagnosis and treatment of primary liver cancer, one-stage liver cancer resection is feasible after evaluation by the liver cancer surgery expert group
* 6)No previous anti-HCC treatment.
* 7)Eastern Co-operative Group performance status 2 or less.
* 8)Liver function: Child's A or B (score \< 7).

Exclusion Criteria:

* 1)Patients with definite tumor thrombus and distant metastasis in the main portal vein and inferior vena cava;
* 2\) Allergy to the components of intervention-related drugs such as lipiodol and chemotherapeutic drugs;
* 3\) Local treatment (including intervention, surgery, ablation, etc.) and systemic treatment (chemotherapy, targeted drugs and immune checkpoint inhibitors, etc.) for liver cancer within the past 2 months